Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Esketamine in Treatment-Resistant Depression
NCT01640080Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Jun 2012; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT01640080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640080.